|SEQ_NO||1||Date of announcement||2023/08/11||Time of announcement||13:36:08|
|Subject||Announcement of TTY Biopharm's unaudited income information in July 2023|
|Date of events||2023/08/11||To which item it meets||paragraph 53|
|Statement||1.Date of occurrence of the event:2023/08/11
2.Company name:TTY Biopharm Co., Ltd.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $422,970 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $87,130 thousands, and a consolidated income before tax of $121,876 thousands in July 2023; net income attributed to stockholders of the company was $97,180 thousands; EPS is $0.39.
Year-to-date consolidated net sales was $2,850,865 thousands (in NT dollars unaudited), a consolidated operating profit was $666,512 thousands and consolidated income before tax was $808,607 thousands until July 2023; year-to-date net income attributed to stockholders of the company was $644,554 thousands; EPS is $2.59.
7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail.